Millions more Americans could access obesity drugs after Trump’s deals with Eli Lilly, Novo Nordisk

CNBC November 7, 2025
Annika Kim Constantino

Key Points

– President Donald Trump struck landmark deals with Eli Lilly and Novo Nordisk that could mark a turning point in access to their costly blockbuster obesity drugs.

– Medicare will start covering GLP-1s for obesity for certain patients for the first time beginning in mid-2026 – a shift that some experts say will open access to millions of older adults and could spur more employers and other private insurers to follow suit.

– The deals could also address gaps in access for patients with limited or no insurance coverage for obesity drugs by offering the treatments at a discount on the Trump administration’s direct-to-consumer website, TrumpRx.gov.

President Donald Trump on Thursday struck landmark deals with Eli...

Today's Sponsors

Today's Sponsor